BioSpace News Archive

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial evaluating the efficacy and safety of JZP-258 for the treatment of idiopathic hypersomnia,

Primary study results on the 20,000 patients anticipated in 2019 to validate the clinical utility of routine screening for microdeletion genetic conditions

Dr. Toselli’s presentation will discuss recent company updates.

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerative Medicine conference 2018 in Valencia, Spain on Monday December 3, 2018.

IQVIA™ (NYSE:IQV) today announced that Napo Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has selected Orchestrated Customer Engagement (OCE), IQVIA Technologies’ innovative commercial solutions suite, to support Napo’s growing commercial organization and enable it to work more closely with healthcare providers.

CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, “rhCollagen”), today announced financial results for the third quarter ended September 30, 2018 and provided an update on the Company’s business developments.

pMD, the innovation leader in health care technology, announced that it has been ranked among the 100 Fastest Growing Private Companies in the Bay Area by the San Francisco Business Times’ 27th annual FAST 100 list.

Q-Flow is designed to improve business processes and increase customer satisfaction and engagement, while offering higher operational efficiency for the business.

The note is convertible into 89.75% of the shares of GLDH at the option of the Company.

Recognition for pioneering new approaches in T cell immunotherapy